Page last updated: 2024-11-06

2-methyl-4-isothiazolin-3-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methyl-4-isothiazolin-3-one: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methylisothiazolinone : A 1,2-thazole that is 4-isothiazolin-3-one bearing a methyl group on the nitrogen atom. It is a powerful biocide and preservative and is the minor active ingredient in the commercial product Kathon(TM). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID39800
CHEMBL ID1620780
CHEBI ID53620
SCHEMBL ID113898
SCHEMBL ID17863
MeSH IDM0057852

Synonyms (71)

Synonym
n-methyl-3-oxodihydro isothiazole
methylisothiazolinone
caswell no. 572a
2-methyl-2h-isothiazol-3-one
einecs 220-239-6
2-methyl-4-isothiazolin-3-one
2-methyl-3(2h)-isothiazolone
3(2h)-isothiazolone, 2-methyl-
2682-20-4
MIT ,
2-methyl-1,2-thiazol-3-one
2-methyl-1,2-thiazol-3(2h)-one
CHEBI:53620 ,
AKOS007930246
2-methylisothiazol-3(2h)-one
2-methyl-4-isothiazolin-3-one (mi)
kordek 50
acticide m 10
2-methyl-3-isothiazolone
mt 10
kb 838
mit 950
n-methylisothiazolin-3-one
2-methyl-4-isothiazoline-3-ketone
microcare mt
2-methyl-4-isothiazoline-3-one
229d0e1qfa ,
bestcide 600
kathon cg 243
unii-229d0e1qfa
acticide m 20
hsdb 8200
mit (biocide)
kordek 50c
kordek mlx
neolone
kordek 573f
FT-0601044
AM84857
methylisothiazolinone [ii]
methylisothiazolinone [inci]
methylisothiazolinone [vandf]
methylisothiazolinone [mart.]
methylisothiazolinone [mi]
2-methyl-4-isothiazolinone
SCHEMBL113898
SCHEMBL17863
NCGC00357093-01
dtxcid0014259
dtxsid2034259 ,
tox21_303814
cas-2682-20-4
W-107150
CHEMBL1620780
2-methyl-3(2h)-isothiazolone #
n-methyl-3-oxodihydroisothiazole
2-methyl-4-isothiazolin-3-one, analytical standard
2-methyl-4-isothiazolin-3-one, 95%
neolone 950; 2-methyl-4-isothiazolin-3-one; 2-methylisothiazol-3-one
BBL104136
STL557951
Q423870
F21330
2-methyl-4-isothiazolin-3-one 100 microg/ml in acetonitrile
CS-W011236
2682-20-4 (free base)
HY-W010520
EN300-1708622
2-methyl-2,3-dihydro-1,2-thiazol-3-one
methylisothiazolinone free base
Z3227502095

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Here, we show that a brief exposure to methylisothiazolinone, a widely used industrial and household biocide, is highly toxic to cultured neurons but not to glia."( In vitro neurotoxicity of methylisothiazolinone, a commonly used industrial and household biocide, proceeds via a zinc and extracellular signal-regulated kinase mitogen-activated protein kinase-dependent pathway.
Aizenman, E; Du, S; McLaughlin, B; Pal, S, 2002
)
0.31
"The information provided does not support the safe use of MI as a preservative in rinse-off cosmetic products up to a concentration limit of 100 ppm from the view of induction of contact allergy."( Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on the safety of the use of Methylisothiazolinone (MI) (P94), in cosmetic products (sensitisation only).
Giménez-Arnau, AM, 2016
)
0.43
" We therefore suggest that a systemic toxicity approach should be considered to comprehensively understand the adverse health effects of humidifier disinfectant misuse."( Early life exposure of a biocide, CMIT/MIT causes metabolic toxicity via the O-GlcNAc transferase pathway in the nematode C. elegans.
Choi, J; Kim, Y, 2019
)
0.51
" The Panel reviewed relevant animal and human data provided in this safety assessment and in a previously published safety assessment of MI and concluded that MI is safe for use in rinse-off cosmetic products at concentrations up to 100 ppm and safe in leave-on cosmetic products when they are formulated to be nonsensitizing, which may be determined based on a quantitative risk assessment."( Amended Safety Assessment of Methylisothiazolinone as Used in Cosmetics.
Belsito, DV; Bergfeld, WF; Boyer, I; Burnett, CL; Gill, LJ; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The study was designed as a double-blind, placebo-controlled, dose-response ROAT preceded by a diagnostic patch testing."( An evaluation of dose/unit area and time as key factors influencing the elicitation capacity of methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) in MCI/MI-allergic patients.
Gray, JE; Lerbaek, A; McNamee, PM; Menné, T; Wooder, M; Zachariae, C, 2006
)
0.33
" At the end of the dosing period, organs were weighed and histological examinations performed."( Effects of a 28-day oral exposure to a 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one biocide formulation in Sprague-Dawley rats.
Pelletier, G; Poon, R; Rigden, M; Valli, VE, 2014
)
0.66
" We have examined the human metabolism of methylisothiazolinone and chloromethylisothiazolinone after oral dosage of stable isotope-labelled analogues."( Urinary excretion kinetics of the metabolite N-methylmalonamic acid (NMMA) after oral dosage of chloromethylisothiazolinone and methylisothiazolinone in human volunteers.
Kraus, T; Schettgen, T, 2017
)
0.46
" We have previously examined the human metabolism of MI and MCI after oral dosage of isotope-labelled analogues in human volunteers and confirmed N-methylmalonamic acid to be a major, but presumably unspecific human urinary metabolite."( New data on the metabolism of chloromethylisothiazolinone and methylisothiazolinone in human volunteers after oral dosage: excretion kinetics of a urinary mercapturic acid metabolite ("M-12").
Bertram, J; Kraus, T; Schettgen, T, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antifouling biocideA compound that inhibits the growth of marine organisms.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1,2-thiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency28.25760.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency54.93890.002541.796015,848.9004AID1347395; AID1347397; AID1347398
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.94103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.63790.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency61.64480.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency4.36260.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency37.86520.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency29.35640.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency63.70930.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency29.60330.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency56.13730.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency61.13060.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency68.58960.000229.305416,493.5996AID1259244
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency8.34340.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency68.58960.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency68.58960.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (339)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (1.77)18.7374
1990's37 (10.91)18.2507
2000's28 (8.26)29.6817
2010's205 (60.47)24.3611
2020's63 (18.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.98 (24.57)
Research Supply Index5.99 (2.92)
Research Growth Index5.79 (4.65)
Search Engine Demand Index72.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (1.53%)5.53%
Reviews21 (5.36%)6.00%
Case Studies122 (31.12%)4.05%
Observational3 (0.77%)0.25%
Other240 (61.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]